93 related articles for article (PubMed ID: 17766651)
1. Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference.
Hempel G; Boos J
Oncologist; 2007 Aug; 12(8):924-6. PubMed ID: 17766651
[No Abstract] [Full Text] [Related]
2. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
Mathijssen RH; de Jong FA; Loos WJ; van der Bol JM; Verweij J; Sparreboom A
Oncologist; 2007 Aug; 12(8):913-23. PubMed ID: 17766650
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of fixed dosing of new anticancer agents in phase I studies.
Levêque D
Anticancer Res; 2008; 28(5B):3075-7. PubMed ID: 19031959
[TBL] [Abstract][Full Text] [Related]
4. [Use of body weight and body surface area in dosing of anticancer agents in adult patients].
Levêque D
Bull Cancer; 2007 Jul; 94(7):647-51. PubMed ID: 17723945
[TBL] [Abstract][Full Text] [Related]
5. [Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?].
Lehne G; Bjørheim J; Saeter G
Tidsskr Nor Laegeforen; 2007 Apr; 127(8):1040-4. PubMed ID: 17457389
[TBL] [Abstract][Full Text] [Related]
6. [Lower costs for anticancer drugs by safety margin around calculated dose and by fine-tuning on ampoule strength].
Mertens S; de Jongh FE
Ned Tijdschr Geneeskd; 2009; 153():B162. PubMed ID: 19785801
[TBL] [Abstract][Full Text] [Related]
7. Cautious arguments in favor of body surface area-based dosing.
Schuler U
J Clin Oncol; 2002 Oct; 20(20):4270; author reply 4270-1. PubMed ID: 12377974
[No Abstract] [Full Text] [Related]
8. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
Wang DD; Zhang S; Zhao H; Men AY; Parivar K
J Clin Pharmacol; 2009 Sep; 49(9):1012-24. PubMed ID: 19620385
[TBL] [Abstract][Full Text] [Related]
9. Getting the right dose in cancer chemotherapy--time to stop using surface area?
Newell DR
Br J Cancer; 2002 Apr; 86(8):1207-8. PubMed ID: 11953873
[No Abstract] [Full Text] [Related]
10. Body surface area in dosing anticancer agents: scratch the surface!
Miller AA
J Natl Cancer Inst; 2002 Dec; 94(24):1822-3. PubMed ID: 12488468
[No Abstract] [Full Text] [Related]
11. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
12. Conventional dosing of anticancer agents: precisely wrong or just inaccurate?
Bins S; Ratain MJ; Mathijssen RH
Clin Pharmacol Ther; 2014 Apr; 95(4):361-4. PubMed ID: 24646486
[No Abstract] [Full Text] [Related]
13. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
14. The scientific basis of body surface area-based dosing.
Chatelut E; Puisset F
Clin Pharmacol Ther; 2014 Apr; 95(4):359-61. PubMed ID: 24646485
[No Abstract] [Full Text] [Related]
15. Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
Felici A; Verweij J; Sparreboom A
Eur J Cancer; 2002 Sep; 38(13):1677-84. PubMed ID: 12175683
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma.
Picton SV; Keeble J; Holden V; Errington J; Boddy AV; Veal GJ
Cancer Chemother Pharmacol; 2009 Mar; 63(4):749-52. PubMed ID: 18607591
[TBL] [Abstract][Full Text] [Related]
17. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
Mould DR; Sweeney K; Duffull SB; Neylon E; Hamlin P; Horwitz S; Sirotnak F; Fleisher M; Saunders ME; O'Connor OA
Clin Pharmacol Ther; 2009 Aug; 86(2):190-6. PubMed ID: 19474785
[TBL] [Abstract][Full Text] [Related]
18. [Dose expression of antineoplastic drugs].
Favre R; Duffaud F; Erard G
Rev Med Interne; 1996; 17(7):586-96. PubMed ID: 8881387
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Li J; Jameson MB; Baguley BC; Pili R; Baker SD
Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
[TBL] [Abstract][Full Text] [Related]
20. BSA-based dosing and alternative approaches.
Sparreboom A
Clin Adv Hematol Oncol; 2005 Jun; 3(6):448-50. PubMed ID: 16167020
[No Abstract] [Full Text] [Related]
[Next] [New Search]
